Suven Life Sciences Q2 FY27 Results: Net Loss Widens to ₹10,694 Lakhs
Suven Life Sciences reported a consolidated net loss of ₹10,694.21 lakhs for Q2 FY27, up from ₹7,730.99 lakhs in Q2 FY26. Standalone net loss was ₹1,638.13 lakhs versus ₹1,544.51 lakhs. The company provided updates on its clinical pipeline, including Phase 3 trials for Alzheimer's and narcolepsy.
The substantial increase in net losses and the widening gap in financial performance compared to the previous year are material events that are likely to impact investor sentiment and the company's stock price.
The company reported a significant increase in net losses on both standalone and consolidated bases for the quarter and half-year ended September 30, 2026, compared to the previous year.
Suven Life Sciences Limited announced its unaudited financial results for the quarter and half year ended September 30, 2026. The Board of Directors approved the standalone and consolidated financial results along with the auditors' review reports during a meeting held on November 5, 2026.
For the quarter ended September 30, 2026, the company reported a standalone net loss of ₹1,638.13 lakhs, compared to a loss of ₹1,544.51 lakhs in the same period last year. Total income for the quarter stood at ₹793.30 lakhs, with expenses at ₹2,431.43 lakhs.
On a consolidated basis, the net loss for the quarter widened significantly to ₹10,694.21 lakhs, from ₹7,730.99 lakhs in the corresponding quarter of the previous year. Total consolidated income was ₹793.30 lakhs, while total consolidated expenses amounted to ₹11,487.51 lakhs.
For the half-year ended September 30, 2026, the standalone net loss was ₹3,250.04 lakhs, an increase from ₹3,022.38 lakhs in the prior year. The consolidated net loss for the half-year also increased to ₹23,455.24 lakhs from ₹12,882.68 lakhs in the previous year.
In terms of clinical development, Suven provided updates on its pipeline: SUVN-502 is in its Global Phase 3 Trial for Alzheimer’s Dementia, with the last patient visit expected in Q1 2027. SUVN-G3031 is progressing in its Phase-3 study for narcolepsy. SUVN-911 completed a Phase 2B study successfully and targets a Global Phase-3 initiation in Q2 2027. SUVN-D4010 initiated a Phase-2 Proof of Concept study in October 2026, and SUVN-I6107 completed its Phase 1 study with toxicological studies underway.
What to do with a filing like this
Suven Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Suven Life Sciences Limited. Read the original for the full detail.